Assembly Biosciences (NASDAQ:ASMB) Price Target Raised to $43.00 at Guggenheim

Assembly Biosciences (NASDAQ:ASMB) had its price objective raised by research analysts at Guggenheim from $39.00 to $43.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price target points to a potential upside of 48.22% from the stock’s current price.

Several other research analysts also recently weighed in on ASMB. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research note on Thursday, March 26th. Wall Street Zen raised Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.75.

Assembly Biosciences Price Performance

NASDAQ ASMB opened at $29.01 on Monday. The business has a 50 day simple moving average of $28.00 and a two-hundred day simple moving average of $30.09. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $39.71. The stock has a market capitalization of $460.10 million, a PE ratio of -39.20 and a beta of 1.15.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%.The business had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million. On average, analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC grew its holdings in shares of Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares in the last quarter. Geode Capital Management LLC lifted its stake in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 3,312 shares in the last quarter. Ellsworth Advisors LLC acquired a new position in shares of Assembly Biosciences during the 3rd quarter worth approximately $852,000. Vanguard Group Inc. grew its position in shares of Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock valued at $12,854,000 after purchasing an additional 248,287 shares in the last quarter. Finally, Patient Square Capital LP purchased a new stake in shares of Assembly Biosciences in the third quarter valued at approximately $3,461,000. Hedge funds and other institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.